ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
,ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
,ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
, ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
c c c c c c c c
1. Acwomancdiagnosedcwithcobsessive–
compulsivecdisorderchascbeencprescribedcoralcparoxetinechydrochloride.cWhatciscthec
expectedceffectcforcthiscprescription?
A. Curativeceffectconcsymptoms
B. Systemicceffectconcsymptoms
C. Localceffectconcsymptoms
D. Parenteralceffectconcsymptoms
ANS:c B
Rationale:cDrugscthatcproducecsystemicceffectscarectakencintocthecbody,ccirculatedcthroughcthe
cbloodstreamctoctheircsitescofcactioncincvariouscbodyc tissues,candceventuallyceliminatedcfromcth
ecbody.cCurativecagentscarecgivenctoccurecacdiseasecprocess.cIncthisccase,cparoxetinechydrochlo
ridecwillccontrolcthecsymptomscbutcnotccurecthecdisorder.cDrugscwithclocalceffects,csuchcascsuns
creencandclocalcanesthetics,cactcmainlycatcthecsitecofcapplication.cParoxetinechydrochlorideciscn
otcadministeredcparenterally.cParenteralcagentscarecadministeredcsubcutaneously,cintramuscul
arly,corcintravenously.
PTS: 1 REF: p.c3,cIntroduction OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc
TOP: Chapter:c1:cThecFoundationcofcPharmacology:cQualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:c CognitivecLevel:cUnderstand NOT:c MultiplecChoice
2. Acclientchascbeencprescribedcancantibiotic.cThiscmedicationciscacnaturallycoccurring
substancecthatchascbeenccheG
mRicA
alDlyEm
SoBdOifOieSd.TWhaOtcM
.C iscanothercnamecforcthisctypecofcmedic
ation?
A. Syntheticcdrug
B. Semisyntheticcdrug
C. Biotechnologycdrug
D. Prototypecdrug
ANS:c B
Rationale:cSemisyntheticcdrugsc(e.g.,cmanycantibiotics)carecnaturallycoccurringcsubstancescthat
chavecbeencchemicallycmodified.cSyntheticcdrugscarecmorecstandardizedcinctheircchemicalcchara
cteristics,cmorecconsistentcinctheirceffects,candclessclikelyctocproducecallergiccreactions.cBiotech
nologycdrugscinvolvecmanipulatingcDNAcandcRNAcandcrecombiningcgenescintochybridcmolec
ulescthatccancbecinsertedcintoclivingcorganisms.cPrototypecdrugscarecthecfirstcdrugcofcacparticular
cgroupctocbecdeveloped.
PTS: 1 REF: p.c3,cDrugcSources OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc
TOP: Chapter:c1:cThecFoundationcofcPharmacology:cQualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:c CognitivecLevel:cUnderstand NOT:c MultiplecChoice
3. Whichcclassificationcappliesctocmorphine?
A. Centralcnervouscsystemcdepressant
B. Centralcnervouscsystemcstimulant
ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
,ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
,ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
, ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
c c c c c c c c
1. Acwomancdiagnosedcwithcobsessive–
compulsivecdisorderchascbeencprescribedcoralcparoxetinechydrochloride.cWhatciscthec
expectedceffectcforcthiscprescription?
A. Curativeceffectconcsymptoms
B. Systemicceffectconcsymptoms
C. Localceffectconcsymptoms
D. Parenteralceffectconcsymptoms
ANS:c B
Rationale:cDrugscthatcproducecsystemicceffectscarectakencintocthecbody,ccirculatedcthroughcthe
cbloodstreamctoctheircsitescofcactioncincvariouscbodyc tissues,candceventuallyceliminatedcfromcth
ecbody.cCurativecagentscarecgivenctoccurecacdiseasecprocess.cIncthisccase,cparoxetinechydrochlo
ridecwillccontrolcthecsymptomscbutcnotccurecthecdisorder.cDrugscwithclocalceffects,csuchcascsuns
creencandclocalcanesthetics,cactcmainlycatcthecsitecofcapplication.cParoxetinechydrochlorideciscn
otcadministeredcparenterally.cParenteralcagentscarecadministeredcsubcutaneously,cintramuscul
arly,corcintravenously.
PTS: 1 REF: p.c3,cIntroduction OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc
TOP: Chapter:c1:cThecFoundationcofcPharmacology:cQualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:c CognitivecLevel:cUnderstand NOT:c MultiplecChoice
2. Acclientchascbeencprescribedcancantibiotic.cThiscmedicationciscacnaturallycoccurring
substancecthatchascbeenccheG
mRicA
alDlyEm
SoBdOifOieSd.TWhaOtcM
.C iscanothercnamecforcthisctypecofcmedic
ation?
A. Syntheticcdrug
B. Semisyntheticcdrug
C. Biotechnologycdrug
D. Prototypecdrug
ANS:c B
Rationale:cSemisyntheticcdrugsc(e.g.,cmanycantibiotics)carecnaturallycoccurringcsubstancescthat
chavecbeencchemicallycmodified.cSyntheticcdrugscarecmorecstandardizedcinctheircchemicalcchara
cteristics,cmorecconsistentcinctheirceffects,candclessclikelyctocproducecallergiccreactions.cBiotech
nologycdrugscinvolvecmanipulatingcDNAcandcRNAcandcrecombiningcgenescintochybridcmolec
ulescthatccancbecinsertedcintoclivingcorganisms.cPrototypecdrugscarecthecfirstcdrugcofcacparticular
cgroupctocbecdeveloped.
PTS: 1 REF: p.c3,cDrugcSources OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc
TOP: Chapter:c1:cThecFoundationcofcPharmacology:cQualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:c CognitivecLevel:cUnderstand NOT:c MultiplecChoice
3. Whichcclassificationcappliesctocmorphine?
A. Centralcnervouscsystemcdepressant
B. Centralcnervouscsystemcstimulant
ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
